Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: Challenges in practice

PharmacoEconomics

Volumn 29, Issue 8, 2011, Pages 719-730

  Parker, Mark ^a   Haycox, Alan ^a   Graves, Jane ^a  

^a UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

Author keywords

Constipation; Prucalopride; Quality adjusted life years; Quality of life; Utility measurement

Indexed keywords

PRUCALOPRIDE;

ARTICLE; CHRONIC CONSTIPATION; CONSTIPATION; DISEASE SEVERITY; GASTROINTESTINAL SYMPTOM; HUMAN; MATHEMATICAL MODEL; PAIN; PATIENT ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; STRUCTURED QUESTIONNAIRE; TREATMENT OUTCOME;

BENZOFURANS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; CONSTIPATION; COST-BENEFIT ANALYSIS; HEALTH STATUS; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 79960127717     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11588360-000000000-00000     Document Type: Article

References (22)

1. National Institute for Health and Clinical Excellence. Single technology appraisal: specification for manufacturer/ sponsor submission of evidence. London: NICE, 2009 Oct
2. National Institute for Health and Clinical Excellence. Guide to themethods of technology appraisal. London: NICE, 2008 Jun
3. Brazier JE, Yang Y, Tsuchiya A, et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010; 11 (2): 215-25
4. Buxton MJ, Lacey LA, Feagan BG, et al. Mapping from disease- specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's disease and measures of utility. Value Health 2007; 10 (3): 214-20 (Pubitemid 46802279)
5. Brazier J, Czoski-Murray C, Roberts J, et al. The King's Health Questionnaire: estimation of a preference-based index from a condition-specific measure. Med Decis Making 2008; 28 (1): 113-26
6. Camilleri M, Kerstens R, Rykx A, et al. A placebocontrolled trial of prucalopride for severe chronic constipation. N Eng J Med 2008; 358 (22): 2344-54 (Pubitemid 351749158)
7. Tack J, Van Outryve M, Beyens G, et al. Prucalopride (Resolor-) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 357-65
8. Quigley EMM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation: a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 315-8
9. Marquis P, de la Loge C, Dubois D, et al. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005; 40 (5): 540-51 (Pubitemid 40676247)
10. Dubois D, Gilet H, Viala-Danten M, et al. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation - Quality of Life questionnaire in Prucalopride (RESOLOR-) trials for chronic constipation. Neurogastroenterol Motility 2010; 22: c54-63
11. Frank L, Flynn J, Rothman M. Use of a self-report constipation questionnaire with older adults in long-term care. Gerontologist 2001; 4 (6): 778-86 (Pubitemid 33139635)
12. Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scandinavian J Gastroenterol 1999; 34: 870-7 (Pubitemid 29470564)
13. Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes 2009 Mar 31; 7: 27
14. Ara R, Brazier J. Deriving an algorithmto convert the 8 mean SF-36 dimension scores into a mean EQ-5D preferencebased score from published studies (where patient level data are not available).Value Health 2009; 12 (2): 346-53
15. Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes 2009 Mar 31; 7: 27
16. Franks P, Lubetkin EI, Gold MR, et al. Mapping the SF-12 to the EuroQol EQ-5D Index in a national US Sample. Med Decis Making 2004; 24 (3): 247-54 (Pubitemid 38656308)
17. Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5Dutility values by response mapping. Med Decis Making 2006; 26 (1): 18-29 (Pubitemid 43134124)
18. Gray AM, Rivero-Arias O, Willison KD. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006; 26 (1): 18-29 (Pubitemid 43134124)
19. Patient Reported Outcomes (PRO) Newsletter 2008; 40 [online]. Available from URL: images/PDF/pron40-final.pdf [Accessed 2011 Feb 9]
20. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 Mar; 21 (2): 271-92 (Pubitemid 34143147)
21. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003 Apr; 56 (4): 317-25 (Pubitemid 36593310)
22. Brazier JE, Roberts JR. The estimation of a preferencebased index from the SF-12. Med Care 2004; 42: 851-9